Drug Shortage Report for APRESOLINE
| Report ID | 58938 |
| Drug Identification Number | 00723754 |
| Brand name | APRESOLINE |
| Common or Proper name | Hydralazine Hydrochloride for injection |
| Company Name | STERIMAX INC |
| Market Status | DORMANT |
| Active Ingredient(s) | HYDRALAZINE HYDROCHLORIDE |
| Strength(s) | 20MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS |
| Packaging size | 10 vials |
| ATC code | C02DB |
| ATC description | ARTERIOLARSMOOTH MUSCLE, AGENTS ACTING ON |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2018-09-28 |
| Actual start date | |
| Estimated end date | |
| Actual end date | 2019-02-27 |
| Shortage status | Resolved |
| Updated date | 2019-02-28 |
| Company comments | Product is on 125% allocation at McKesson. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 2770 PORTLAND DRIVE OAKVILLE, ONTARIO CANADA L6H 6R4 |
| Company contact information | 1-800-881-3550 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2018-08-24 | English | Compare |